SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
+5.52%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.07B
AUM Growth
+$2.07B
(-13%)
Cap. Flow
-$298M
Cap. Flow
% of AUM
-14.38%
Top 10 Holdings %
Top 10 Hldgs %
38.29%
Holding
115
New
23
Increased
36
Reduced
14
Closed
20
Top Buys
| 1 |
Elevance Health
ELV
|
$58.1M |
| 2 |
Amazon
AMZN
|
$57.8M |
| 3 |
Yum! Brands
YUM
|
$52.3M |
| 4 |
Royalty Pharma
RPRX
|
$38.6M |
| 5 |
89bio
ETNB
|
$33.7M |
Top Sells
| 1 |
Otis Worldwide
OTIS
|
$102M |
| 2 |
Tapestry
TPR
|
$83M |
| 3 |
Las Vegas Sands
LVS
|
$78.1M |
| 4 |
Union Pacific
UNP
|
$56.3M |
| 5 |
AT&T
T
|
$54.3M |
Sector Composition
| 1 | Healthcare | 54.01% |
| 2 | Consumer Discretionary | 14.68% |
| 3 | Technology | 7.64% |
| 4 | Communication Services | 6.4% |
| 5 | Consumer Staples | 5.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Johnson & Johnson
JNJ
$429B
| $8.57M | 0.36% |
55,290
+26,000
| +89% | +$4.03M |
|
52
Arcutis Biotherapeutics
ARQT
$1.91B
| $7.47M | 0.32% |
+679,391
| New | +$7.47M |
|
53
Sana Biotechnology
SANA
$759M
| $6.91M | 0.29% |
+2,113,800
| New | +$6.91M |
|
|
AKLI
54
DELISTED
Akili, Inc. Common Stock
AKLI
| $6.15M | 0.26% |
3,841,718
+217,555
| +6% | +$348K |
|
|
MREO
55
Mereo BioPharma
MREO
$275M
| $5.21M | 0.22% |
7,364,438
| – | – |
|
56
BioNTech
BNTX
$24.1B
| $5.1M | 0.22% |
40,970
+10,370
| +34% | +$1.29M |
|
57
InflaRx
IFRX
$117M
| $4.16M | 0.18% |
2,146,240
| – | – |
|
58
Elanco Animal Health
ELAN
$8.62B
| $4.11M | 0.17% |
436,900
+82,500
| +23% | +$776K |
|
59
Thermo Fisher Scientific
TMO
$183B
| $2.92M | 0.12% |
5,060
+1,700
| +51% | +$980K |
|
60
Natera
NTRA
$23B
| $2.88M | 0.12% |
51,900
| – | – |
|
61
Danaher
DHR
$143B
| $2.8M | 0.12% |
11,127
+3,695
| +50% | +$931K |
|
62
Incyte
INCY
$17B
| $2.72M | 0.11% |
+37,600
| New | +$2.72M |
|
63
AstraZeneca
AZN
$255B
| $2.49M | 0.11% |
35,890
+20,200
| +129% | +$1.4M |
|
|
MOLN
64
Molecular Partners
MOLN
$139M
| $2.42M | 0.1% |
400,000
| – | – |
|
65
Abbott
ABT
$230B
| $2.09M | 0.09% |
20,620
+10,310
| +100% | +$1.04M |
|
66
Illumina
ILMN
$15.2B
| $2.03M | 0.09% |
8,730
+5,920
| +211% | +$1.38M |
|
67
Gilead Sciences
GILD
$140B
| $1.88M | 0.08% |
+22,700
| New | +$1.88M |
|
68
Galapagos
GLPG
$2.06B
| $1.82M | 0.08% |
47,200
| – | – |
|
69
IQVIA
IQV
$31.4B
| $1.43M | 0.06% |
7,175
+4,216
| +142% | +$839K |
|
70
Medtronic
MDT
$118B
| $1.41M | 0.06% |
17,460
+8,094
| +86% | +$653K |
|
|
RETA
71
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.37M | 0.06% |
+15,100
| New | +$1.37M |
|
72
CVS Health
CVS
$93B
| $1.28M | 0.05% |
17,170
+14,300
| +498% | +$1.06M |
|
73
argenx
ARGX
$44.2B
| $1.26M | 0.05% |
3,390
+1,870
| +123% | +$697K |
|
74
Sanofi
SNY
$122B
| $1.23M | 0.05% |
22,610
| – | – |
|
75
Spyre Therapeutics
SYRE
$1.02B
| $1.18M | 0.05% |
4,059,894
| – | – |
|